{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:53:24Z","timestamp":1792900404986,"version":"4.5.0"},"publisher-location":"New York, NY","reference-count":31,"publisher":"Springer US","isbn-type":[{"value":"9781071629093","type":"print"},{"value":"9781071629109","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-2910-9_20","type":"book-chapter","created":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T04:01:09Z","timestamp":1672545669000},"page":"271-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inhibitors of Glucosylceramide Synthase"],"prefix":"10.1007","author":[{"given":"James A.","family":"Shayman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Hinkovska-Galcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,1]]},"reference":[{"issue":"12","key":"20_CR1","doi-asserted-by":"publisher","first-page":"F996","DOI":"10.1152\/ajprenal.00393.2015","volume":"309","author":"JA Shayman","year":"2015","unstructured":"Shayman JA (2015) Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective. Am J Physiol Renal Physiol 309(12):F996\u2013F999. https:\/\/doi.org\/10.1152\/ajprenal.00393.2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"20_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00731489","volume":"13","author":"NS Radin","year":"1996","unstructured":"Radin NS (1996) Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J 13(2):153\u2013157. https:\/\/doi.org\/10.1007\/BF00731489","journal-title":"Glycoconj J"},{"issue":"8","key":"20_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","volume":"35","author":"JA Shayman","year":"2010","unstructured":"Shayman JA (2010) ELIGLUSTAT TARTRATE: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future 35(8):613\u2013620","journal-title":"Drugs Future"},{"issue":"3","key":"20_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2174\/0929867327666200114112728","volume":"28","author":"H Wang","year":"2021","unstructured":"Wang H, Shen Y, Zhao L, Ye Y (2021) 1-Deoxynojirimycin and its derivatives: a mini review of the literature. Curr Med Chem 28(3):628\u2013643. https:\/\/doi.org\/10.2174\/0929867327666200114112728","journal-title":"Curr Med Chem"},{"issue":"9214","key":"20_CR5","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355(9214):1481\u20131485. https:\/\/doi.org\/10.1016\/S0140-6736(00)02161-9","journal-title":"Lancet"},{"issue":"6","key":"20_CR6","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1021\/mp200313e","volume":"8","author":"O Abian","year":"2011","unstructured":"Abian O, Alfonso P, Velazquez-Campoy A, Giraldo P, Pocovi M, Sancho J (2011) Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm 8(6):2390\u20132397. https:\/\/doi.org\/10.1021\/mp200313e","journal-title":"Mol Pharm"},{"issue":"3","key":"20_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","volume":"91","author":"KA McEachern","year":"2007","unstructured":"McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91(3):259\u2013267. https:\/\/doi.org\/10.1016\/j.ymgme.2007.04.001","journal-title":"Mol Genet Metab"},{"issue":"11","key":"20_CR8","doi-asserted-by":"publisher","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","volume":"269","author":"FM Platt","year":"1994","unstructured":"Platt FM, Neises GR, Dwek RA, Butters TD (1994) N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269(11):8362\u20138365","journal-title":"J Biol Chem"},{"issue":"7","key":"20_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/s0006-2952(99)00384-6","volume":"59","author":"U Andersson","year":"2000","unstructured":"Andersson U, Butters TD, Dwek RA, Platt FM (2000) N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 59(7):821\u2013829. https:\/\/doi.org\/10.1016\/s0006-2952(99)00384-6","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"20_CR10","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.bcp.2006.12.015","volume":"73","author":"R Steet","year":"2007","unstructured":"Steet R, Chung S, Lee WS, Pine CW, Do H, Kornfeld S (2007) Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol 73(9):1376\u20131383. https:\/\/doi.org\/10.1016\/j.bcp.2006.12.015","journal-title":"Biochem Pharmacol"},{"issue":"36","key":"20_CR11","doi-asserted-by":"publisher","first-page":"26052","DOI":"10.1074\/jbc.M113.463562","volume":"288","author":"CM Ridley","year":"2013","unstructured":"Ridley CM, Thur KE, Shanahan J, Thillaiappan NB, Shen A, Uhl K, Walden CM, Rahim AA, Waddington SN, Platt FM, van der Spoel AC (2013) Beta-glucosidase 2 (GBA2) activity and imino sugar pharmacology. J Biol Chem 288(36):26052\u201326066. https:\/\/doi.org\/10.1074\/jbc.M113.463562","journal-title":"J Biol Chem"},{"issue":"2","key":"20_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1021\/jm901281m","volume":"53","author":"T Wennekes","year":"2010","unstructured":"Wennekes T, Meijer AJ, Groen AK, Boot RG, Groener JE, van Eijk M, Ottenhoff R, Bijl N, Ghauharali K, Song H, O'Shea TJ, Liu H, Yew N, Copeland D, van den Berg RJ, van der Marel GA, Overkleeft HS, Aerts JM (2010) Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J Med Chem 53(2):689\u2013698. https:\/\/doi.org\/10.1021\/jm901281m","journal-title":"J Med Chem"},{"issue":"14","key":"20_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s40265-015-0468-9","volume":"75","author":"LJ Scott","year":"2015","unstructured":"Scott LJ (2015) Eliglustat: a review in Gaucher disease type 1. Drugs 75(14):1669\u20131678. https:\/\/doi.org\/10.1007\/s40265-015-0468-9","journal-title":"Drugs"},{"issue":"6","key":"20_CR14","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1074\/jbc.270.6.2859","volume":"270","author":"CS Rani","year":"1995","unstructured":"Rani CS, Abe A, Chang Y, Rosenzweig N, Saltiel AR, Radin NS, Shayman JA (1995) Cell cycle arrest induced by an inhibitor of glucosylceramide synthase. Correlation with cyclin-dependent kinases. J Biol Chem 270(6):2859\u20132867. https:\/\/doi.org\/10.1074\/jbc.270.6.2859","journal-title":"J Biol Chem"},{"issue":"3","key":"20_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/jcp.1041410316","volume":"141","author":"J Inokuchi","year":"1989","unstructured":"Inokuchi J, Momosaki K, Shimeno H, Nagamatsu A, Radin NS (1989) Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells. J Cell Physiol 141(3):573\u2013583. https:\/\/doi.org\/10.1002\/jcp.1041410316","journal-title":"J Cell Physiol"},{"issue":"6","key":"20_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011239","volume":"5","author":"NS Yew","year":"2010","unstructured":"Yew NS, Zhao H, Hong EG, Wu IH, Przybylska M, Siegel C, Shayman JA, Arbeeny CM, Kim JK, Jiang C, Cheng SH (2010) Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS One 5(6):e11239. https:\/\/doi.org\/10.1371\/journal.pone.0011239","journal-title":"PLoS One"},{"issue":"6","key":"20_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa1508808","volume":"374","author":"S Nair","year":"2016","unstructured":"Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV (2016) Clonal immunoglobulin against Lysolipids in the origin of myeloma. N Engl J Med 374(6):555\u2013561. https:\/\/doi.org\/10.1056\/NEJMoa1508808","journal-title":"N Engl J Med"},{"issue":"7","key":"20_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nm.2171","volume":"16","author":"TA Natoli","year":"2010","unstructured":"Natoli TA, Smith LA, Rogers KA, Wang B, Komarnitsky S, Budman Y, Belenky A, Bukanov NO, Dackowski WR, Husson H, Russo RJ, Shayman JA, Ledbetter SR, Leonard JP, Ibraghimov-Beskrovnaya O (2010) Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med 16(7):788\u2013792. https:\/\/doi.org\/10.1038\/nm.2171","journal-title":"Nat Med"},{"key":"20_CR19","doi-asserted-by":"publisher","first-page":"100470","DOI":"10.1016\/j.jbc.2021.100470","volume":"296","author":"EB Vitner","year":"2021","unstructured":"Vitner EB, Achdout H, Avraham R, Politi B, Cherry L, Tamir H, Yahalom-Ronen Y, Paran N, Melamed S, Erez N, Israely T (2021) Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus. J Biol Chem 296:100470. https:\/\/doi.org\/10.1016\/j.jbc.2021.100470","journal-title":"J Biol Chem"},{"issue":"1","key":"20_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpdd.865","volume":"10","author":"MJ Peterschmitt","year":"2021","unstructured":"Peterschmitt MJ, Crawford NPS, Gaemers SJM, Ji AJ, Sharma J, Pham TT (2021) Pharmacokinetics, pharmacodynamics, safety, and tolerability of Oral Venglustat in healthy volunteers. Clin Pharmacol Drug Dev 10(1):86\u201398. https:\/\/doi.org\/10.1002\/cpdd.865","journal-title":"Clin Pharmacol Drug Dev"},{"key":"20_CR21","doi-asserted-by":"publisher","first-page":"105507","DOI":"10.1016\/j.nbd.2021.105507","volume":"159","author":"M Cosden","year":"2021","unstructured":"Cosden M, Jinn S, Yao L, Gretzula CA, Kandebo M, Toolan D, Hatcher NG, Ma L, Lemaire W, Adam GC, Burlein C, Minnick C, Flick R, Watt ML, Mulhearn J, Fraley M, Drolet RE, Marcus JN, Smith SM (2021) A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiol Dis 159:105507. https:\/\/doi.org\/10.1016\/j.nbd.2021.105507","journal-title":"Neurobiol Dis"},{"key":"20_CR22","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.2147\/DDDT.S77760","volume":"9","author":"LL Bennett","year":"2015","unstructured":"Bennett LL, Turcotte K (2015) Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease. Drug Des Devel Ther 9:4639\u20134647. https:\/\/doi.org\/10.2147\/DDDT.S77760","journal-title":"Drug Des Devel Ther"},{"key":"20_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bcmd.2018.04.001","volume":"71","author":"PK Mistry","year":"2018","unstructured":"Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, Cox GF, Danda S, Dragosky M, Drelichman G, El-Beshlawy A, Fraga C, Freisens S, Gaemers S, Hadjiev E, Kishnani PS, Lukina E, Maison-Blanche P, Martins AM, Pastores G, Petakov M, Peterschmitt MJ, Rosenbaum H, Rosenbloom B, Underhill LH, Cox TM (2018) Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells Mol Dis 71:71\u201374. https:\/\/doi.org\/10.1016\/j.bcmd.2018.04.001","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"20_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1194\/jlr.M021261","volume":"53","author":"SD Larsen","year":"2012","unstructured":"Larsen SD, Wilson MW, Abe A, Shu L, George CH, Kirchhoff P, Showalter HD, Xiang J, Keep RF, Shayman JA (2012) Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res 53(2):282\u2013291. https:\/\/doi.org\/10.1194\/jlr.M021261","journal-title":"J Lipid Res"},{"issue":"20","key":"20_CR25","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1021\/acschemneuro.0c00558","volume":"11","author":"MW Wilson","year":"2020","unstructured":"Wilson MW, Shu L, Hinkovska-Galcheva V, Jin Y, Rajeswaran W, Abe A, Zhao T, Luo R, Wang L, Wen B, Liou B, Fannin V, Sun D, Sun Y, Shayman JA, Larsen SD (2020) Optimization of eliglustat-based glucosylceramide synthase inhibitors as substrate reduction therapy for Gaucher disease type 3. ACS Chem Neurosci 11(20):3464\u20133473. https:\/\/doi.org\/10.1021\/acschemneuro.0c00558","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"20_CR26","first-page":"583","volume":"26","author":"E Ginoulhiac","year":"1950","unstructured":"Ginoulhiac E, Semenza F, Mainardi L (1950) Toxicity and pharmacologic effects of gentisic acid. Boll Soc Ital Biol Sper 26(4):583\u2013585","journal-title":"Boll Soc Ital Biol Sper"},{"issue":"21","key":"20_CR27","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1016\/S0021-9258(18)91935-6","volume":"243","author":"S Basu","year":"1968","unstructured":"Basu S, Kaufman B, Roseman S (1968) Enzymatic synthesis of ceramide-glucose and ceramide-lactose by glycosyltransferases from embryonic chicken brain. J Biol Chem 243(21):5802\u20135804","journal-title":"J Biol Chem"},{"issue":"2","key":"20_CR28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1021\/bi00830a008","volume":"8","author":"P Morell","year":"1969","unstructured":"Morell P, Radin NS (1969) Synthesis of cerebroside by brain from uridine diphosphate galactose and ceramide containing hydroxy fatty acid. Biochemistry 8(2):506\u2013512. https:\/\/doi.org\/10.1021\/bi00830a008","journal-title":"Biochemistry"},{"issue":"5","key":"20_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/s0962-8924(98)01249-5","volume":"8","author":"S Ichikawa","year":"1998","unstructured":"Ichikawa S, Hirabayashi Y (1998) Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol 8(5):198\u2013202. https:\/\/doi.org\/10.1016\/s0962-8924(98)01249-5","journal-title":"Trends Cell Biol"},{"issue":"1","key":"20_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0005-2760(79)90174-7","volume":"573","author":"RR Vunnam","year":"1979","unstructured":"Vunnam RR, Radin NS (1979) Short chain ceramides as substrates for glucocerebroside synthetase. Differences between liver and brain enzymes. Biochim Biophys Acta 573(1):73\u201382. https:\/\/doi.org\/10.1016\/0005-2760(79)90174-7","journal-title":"Biochim Biophys Acta"},{"key":"20_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0076-6879(66)08014-5","volume":"8","author":"BN Ames","year":"1966","unstructured":"Ames BN (1966) Assay of inorganic phosphate, total phosphate, and phosphatases. Methods Enzymol 8:115\u2013118","journal-title":"Methods Enzymol"}],"container-title":["Methods in Molecular Biology","Glycolipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2910-9_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T04:41:49Z","timestamp":1672548109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2910-9_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071629093","9781071629109"],"references-count":31,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2910-9_20","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"1 January 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}